Selvita S.A. (SLV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Selvita S.A. (SLV) has a cash flow conversion efficiency ratio of 0.069x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł21.92 Million ≈ $6.03 Million USD) by net assets (zł316.29 Million ≈ $87.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Selvita S.A. - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Selvita S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Selvita S.A. (SLV) total liabilities for a breakdown of total debt and financial obligations.
Selvita S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Selvita S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jih Lin Technology Co Ltd
TW:5285
|
0.010x |
|
BLE KEDROS REIC EO 1
F:N67
|
N/A |
|
Northcliff Resources Ltd
TO:NCF
|
-0.049x |
|
Compania Espanola de Viviendas en Alquiler SA
MC:CEV
|
0.006x |
|
Achieve Life Sciences Inc
NASDAQ:ACHV
|
-0.835x |
|
Bikurey Hasade Holdings Ltd
TA:BKRY
|
0.080x |
|
Smith-Midland Corp
NASDAQ:SMID
|
0.179x |
|
Aimia Inc
TO:AIM
|
0.110x |
Annual Cash Flow Conversion Efficiency for Selvita S.A. (2015–2024)
The table below shows the annual cash flow conversion efficiency of Selvita S.A. from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Selvita S.A. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł321.88 Million ≈ $88.59 Million |
zł64.07 Million ≈ $17.63 Million |
0.199x | -17.57% |
| 2023-12-31 | zł327.07 Million ≈ $90.01 Million |
zł78.98 Million ≈ $21.74 Million |
0.241x | -12.55% |
| 2022-12-31 | zł273.16 Million ≈ $75.18 Million |
zł75.43 Million ≈ $20.76 Million |
0.276x | -35.11% |
| 2021-12-31 | zł205.55 Million ≈ $56.57 Million |
zł87.47 Million ≈ $24.07 Million |
0.426x | +121.29% |
| 2020-12-31 | zł152.66 Million ≈ $42.01 Million |
zł29.36 Million ≈ $8.08 Million |
0.192x | +113.17% |
| 2019-12-31 | zł47.66 Million ≈ $13.12 Million |
zł4.30 Million ≈ $1.18 Million |
0.090x | -61.73% |
| 2018-12-31 | zł49.19 Million ≈ $13.54 Million |
zł11.60 Million ≈ $3.19 Million |
0.236x | -16.47% |
| 2017-12-31 | zł37.34 Million ≈ $10.28 Million |
zł10.54 Million ≈ $2.90 Million |
0.282x | +350.36% |
| 2016-12-31 | zł55.71 Million ≈ $15.33 Million |
zł-6.28 Million ≈ $-1.73 Million |
-0.113x | +67.84% |
| 2015-12-31 | zł46.88 Million ≈ $12.90 Million |
zł-16.43 Million ≈ $-4.52 Million |
-0.350x | -- |
About Selvita S.A.
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational re… Read more